140. ドラベ症候群 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 116 / 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
12-Lead ECG   
   Gillette Children's Specialty Healthcare
      2017   Phase 1/Phase 2   NCT02815540   United States;
Ataluren   
   NYU Langone Health
      2016   Phase 2   NCT02758626   United States;
CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA.   
   GW Research Ltd
      2015   Phase 3   EUCTR2014-001834-27-PL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-NL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol   
   GW Research Ltd
      2021   Phase 4   NCT05044819   United States;
   Gillette Children's Specialty Healthcare
      2017   Phase 1/Phase 2   NCT02815540   United States;
   Yonsei University
      2020   Phase 3   NCT04611438   Korea, Republic of;
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2018   Phase 1/Phase 2   NCT03467113   United States;
Cannabidiol (CBD)   
   GW Research Ltd
      2015   Phase 3   EUCTR2014-002939-34-NL   Australia;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002939-34-ES   Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-PL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-NL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-GB   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-FR   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-ES   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   -   EUCTR2014-000995-24-PL   France;Poland;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002939-34-GB   Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000995-24-GB   France;Poland;United Kingdom;United States;
      -   Phase 3   EUCTR2014-002939-34-PL   Australia;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol Oral Solution   
   INSYS Therapeutics Inc
      2017   Phase 3   NCT02318563   -
Carbidopa   
   Natsume Jun
      2020   Phase 4   JPRN-jRCTs041190116   Japan;
Clobazam   
   H. Lundbeck A/S
      2015   Phase 3   NCT02187809   Mexico;United States;
      2015   Phase 3   NCT02174094   Mexico;United States;
   ISTITUTO C. MONDINO
      2007   -   EUCTR2007-003702-95-IT   Italy;
   Inserm-ISP Pole Recherches cliniques et thérapeutiques
      2007   -   EUCTR2007-002198-30-IT   Italy;
DIACOMIT (Stiripentol)   
   Meiji Seika Pharma Co., Ltd.
      2012   -   JPRN-JapicCTI-205180   Japan;
EPX-100 (Clemizole HCl)   
   Epygenix
      2020   Phase 2   NCT04462770   Canada;United States;
EPX-100 (Clemizole Hydrochloride)   
   Epygenix
      2019   Phase 1   NCT04069689   United States;
FENFLURAMINE HYDROCHLORIDE   
   Zogenix International Limited
      2019   Phase 3   EUCTR2019-001331-31-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
FENFLURAMINE HYDROCHLORIDE (colorless)   
   Zogenix International Limited
      2017   Phase 3   EUCTR2016-002804-14-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002804-14-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2016   Phase 3   EUCTR2016-002804-14-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
FENFLURAMINE HYDROCHLORIDE (red)   
   Zogenix International Limited
      2017   Phase 3   EUCTR2016-002804-14-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002804-14-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2016   Phase 3   EUCTR2016-002804-14-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
FRISIUM*30CPS   
   ISTITUTO C. MONDINO
      2007   -   EUCTR2007-003702-95-IT   Italy;
   Inserm-ISP Pole Recherches cliniques et thérapeutiques
      2007   -   EUCTR2007-002198-30-IT   Italy;
Fenfluramina Cloridrato   
   ZOGENIX INTERNATIONAL LTD
      2016   Phase 3   EUCTR2015-004167-37-IT   Australia;Belgium;Denmark;France;Germany;Italy;Korea, Republic of;Norway;Spain;Sweden;Switzerland;United Kingdom;
Fenfluramina cloridrato   
   Zogenix International Limited
      2019   Phase 3   EUCTR2019-001331-31-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Fenfluramine   
   University of California, Los Angeles
      2018   -   NCT04437004   United States;
   YAMAMOTO Hideichiro
      2019   Phase 3   JPRN-jRCT2041200095   Australia;Belgium;Canda;Denmark;France;Germany;Italy;Japan;Korea;Netherland;Norway;Spain;Sweeded;UK;US;
Fenfluramine Hydrochloride   
   Zogenix, Inc.
      2018   -   NCT03780127   -
Fenfluramine hydrochloride   
   Zogenix International Limited
      2019   Phase 3   JPRN-JapicCTI-194872   Japan, Europe, Australia;
Fenfluramine hydrochloride (colorless)   
   Zogenix International Limited
      2020   Phase 3   EUCTR2019-001331-31-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002804-14-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2016   Phase 3   EUCTR2016-002804-14-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
Fenfluramine hydrochloride (red)   
   Zogenix International Limited
      2017   Phase 3   EUCTR2016-002804-14-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002804-14-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2016   Phase 3   EUCTR2016-002804-14-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
GWP42003-P   
   GW Research Ltd
      2015   Phase 3   NCT02224703   Australia;Israel;Netherlands;Poland;Spain;United States;
      2015   Phase 3   NCT02224573   -
      2015   Phase 3   EUCTR2014-002939-34-NL   Australia;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002939-34-ES   Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-PL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-NL   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-GB   Australia;France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-FR   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001834-27-ES   France;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   -   EUCTR2014-000995-24-PL   France;Poland;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002939-34-GB   Israel;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000995-24-GB   France;Poland;United Kingdom;United States;
      -   Phase 3   EUCTR2014-002939-34-PL   Australia;Israel;Netherlands;Poland;Spain;United Kingdom;United States;
GWP42003-P 10 mg/kg/day Dose   
   GW Research Ltd
      2014   Phase 2   NCT02091206   United Kingdom;United States;
GWP42003-P 20 mg/kg/day Dose   
   GW Research Ltd
      2015   Phase 3   NCT02091375   France;Poland;United Kingdom;United States;
      2014   Phase 2   NCT02091206   United Kingdom;United States;
GWP42003-P 5 mg/kg/day Dose   
   GW Research Ltd
      2014   Phase 2   NCT02091206   United Kingdom;United States;
Levodopa   
   Natsume Jun
      2020   Phase 4   JPRN-jRCTs041190116   Japan;
Lorcaserin   
   Eisai Inc.
      2020   Phase 3   NCT04572243   Canada;United States;
      2020   -   NCT04457687   -
ME2080 (stiripentol)   
   Meiji Seika Pharma Co., Ltd. (formerly MEIJI SEIKA KAISHA Co., LTD.)
      2010   Phase 3   JPRN-JapicCTI-101116   -
None at this time   
   Takeda Development Center Americas, Inc.
      2019   Phase 2   EUCTR2018-002484-25-PT   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
      2019   Phase 2   EUCTR2018-002484-25-PL   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
Other antiepileptics   
   Inserm-ISP Pole Recherches cliniques et thérapeutiques
      2007   -   EUCTR2007-002198-30-IT   Italy;
PEG   
   Nonomura Hidenori
      2021   Phase 3   JPRN-jRCT2051210074   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russia;Serbia;Spain;Ukraine;United Kingdom;United States;
Placebo   
   Zogenix International Limited
      2019   Phase 3   JPRN-JapicCTI-194872   Japan, Europe, Australia;
STK-001   
   Stoke Therapeutics, Inc
      2021   Phase 2   NCT04740476   United States;
STK-001 - Multiple Ascending Doses   
   Stoke Therapeutics, Inc
      2020   Phase 1/Phase 2   NCT04442295   United States;
STK-001 - Single Ascending Doses   
   Stoke Therapeutics, Inc
      2020   Phase 1/Phase 2   NCT04442295   United States;
Soticlestat   
   Ovid Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-002485-39-PL   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2021   Phase 3   EUCTR2021-002480-22-IT   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Takeda
      2022   Phase 3   NCT05163314   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2021   Phase 3   NCT04940624   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2018   Phase 2   NCT03635073   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2021-002480-22-PL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-NL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-HU   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-GR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-ES   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-BE   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002480-22-LV   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002480-22-FR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Stiripentol   
   Children's Hospital Medical Center, Cincinnati
      2013   -   NCT01983722   United States;
   Cook Children's Health Care System
      2014   -   NCT02239276   United States;
   Mayo Clinic
      2012   Phase 4   NCT01533506   United States;
   University of Colorado, Denver
      2013   -   NCT01835314   United States;
   Yushi InoueNational Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
      2007   -   JPRN-JMA-IIA00014   Japan;
Stiripentolo   
   ISTITUTO C. MONDINO
      2007   -   EUCTR2007-003702-95-IT   Italy;
   Inserm-ISP Pole Recherches cliniques et thérapeutiques
      2007   -   EUCTR2007-002198-30-IT   Italy;
TAK-935   
   Ovid Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-002485-39-PL   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   TAKEDA DEVELOPMENT CENTER AMERICAS INC.
      2021   Phase 3   EUCTR2021-002480-22-IT   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Takeda
      2018   Phase 2   NCT03650452   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
   Takeda Development Center Americas, Inc
      2022   Phase 3   EUCTR2021-002482-17-GR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      -   Phase 3   EUCTR2021-002482-17-BE   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      -   Phase 3   EUCTR2021-002480-22-Outside-EU/EEA   Australia;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Takeda Development Center Americas, Inc.
      2021   Phase 3   EUCTR2021-002480-22-PL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-NL   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-HU   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-GR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-ES   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-002480-22-BE   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002484-25-PT   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
      2019   Phase 2   EUCTR2018-002484-25-PL   Australia;Canada;China;Israel;Poland;Portugal;Spain;United States;
      -   Phase 3   EUCTR2021-002480-22-LV   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2021-002480-22-FR   Australia;Belgium;Canada;China;France;Greece;Hungary;Italy;Japan;Latvia;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
TOPAMAX   
   ISTITUTO C. MONDINO
      2007   -   EUCTR2007-003702-95-IT   Italy;
   Inserm-ISP Pole Recherches cliniques et thérapeutiques
      2007   -   EUCTR2007-002198-30-IT   Italy;
Topiramate   
   ISTITUTO C. MONDINO
      2007   -   EUCTR2007-003702-95-IT   Italy;
   Inserm-ISP Pole Recherches cliniques et thérapeutiques
      2007   -   EUCTR2007-002198-30-IT   Italy;
Turmeric   
   NYU Langone Health
      2018   -   NCT03254680   United States;
Verapamil   
   Gillette Children's Specialty Healthcare
      2012   Phase 2   NCT01607073   United States;
ZX008   
   ZOGENIX INTERNATIONAL LTD
      2016   Phase 3   EUCTR2015-004167-37-IT   Australia;Belgium;Denmark;France;Germany;Italy;Korea, Republic of;Norway;Spain;Sweden;Switzerland;United Kingdom;
   Zogenix International Limited
      2020   Phase 3   EUCTR2019-001331-31-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001331-31-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   JPRN-JapicCTI-194872   Japan, Europe, Australia;
      2019   Phase 3   EUCTR2019-001331-31-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001331-31-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002804-14-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000474-38-GB   Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000474-38-ES   Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000474-38-DE   Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002804-14-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-000474-38-NL   Germany;Netherlands;Spain;United Kingdom;
      2016   Phase 3   EUCTR2015-004167-37-SE   Australia;Belgium;Denmark;France;Germany;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2015-004167-37-GB   Australia;Belgium;Denmark;France;Germany;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2015-004167-37-ES   Australia;Belgium;Denmark;France;Germany;Italy;Korea, Republic of;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2015-004167-37-DK   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2015-004167-37-DE   Australia;Belgium;Denmark;France;Germany;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2015-004167-37-BE   Australia;Belgium;Denmark;France;Germany;Italy;Korea, Republic of;Norway;Spain;Sweden;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-001331-31-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001331-31-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002804-14-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-004167-37-NO   Australia;Belgium;Denmark;France;Germany;Italy;Korea, Republic of;Norway;Spain;Sweden;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2015-004167-37-FR   Australia;Belgium;Denmark;France;Germany;Italy;Korea, Republic of;Norway;Spain;Sweden;Switzerland;United Kingdom;
   Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.
      2016   Phase 3   EUCTR2016-002804-14-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
ZX008 (Fenfluramine Hydrochloride)   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2017   Phase 3   NCT03299842   United States;
      2016   Phase 3   NCT02823145   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   NCT02682927   Canada;United States;
   Zogenix, Inc.
      2019   Phase 3   NCT03936777   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
ZX008 - 0.2 mg/kg/day   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2016   Phase 3   NCT02926898   Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   NCT02826863   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;
ZX008 - 0.4 mg/kg/day   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2016   Phase 3   NCT02926898   Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
ZX008 - 0.8 mg/kg/day   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2016   Phase 3   NCT02826863   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;
ZX008 - 20 mg/day maximum dose   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2016   Phase 3   NCT02926898   Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
ZX008 0.2 to 0.8 mg/kg/day   
   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
      2018   Phase 1/Phase 2   NCT03467113   United States;